AU2020242921B2 - Supraparticle formulations - Google Patents
Supraparticle formulations Download PDFInfo
- Publication number
- AU2020242921B2 AU2020242921B2 AU2020242921A AU2020242921A AU2020242921B2 AU 2020242921 B2 AU2020242921 B2 AU 2020242921B2 AU 2020242921 A AU2020242921 A AU 2020242921A AU 2020242921 A AU2020242921 A AU 2020242921A AU 2020242921 B2 AU2020242921 B2 AU 2020242921B2
- Authority
- AU
- Australia
- Prior art keywords
- supraparticles
- sps
- another example
- payload
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0541—Cochlear electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36036—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the outer, middle or inner ear
- A61N1/36038—Cochlear stimulation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019900910 | 2019-03-19 | ||
| AU2019900910A AU2019900910A0 (en) | 2019-03-19 | Improved supraparticles II | |
| PCT/AU2020/050260 WO2020186304A1 (en) | 2019-03-19 | 2020-03-19 | Supraparticle formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020242921A1 AU2020242921A1 (en) | 2021-10-07 |
| AU2020242921B2 true AU2020242921B2 (en) | 2025-04-03 |
Family
ID=72518918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020242921A Active AU2020242921B2 (en) | 2019-03-19 | 2020-03-19 | Supraparticle formulations |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12551450B2 (https=) |
| EP (1) | EP3941442A4 (https=) |
| JP (1) | JP2022525945A (https=) |
| CN (1) | CN114040753A (https=) |
| AU (1) | AU2020242921B2 (https=) |
| WO (1) | WO2020186304A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117065055B (zh) * | 2022-05-24 | 2025-08-29 | 天津医科大学第二医院 | 一种核壳型纳米酶探针及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019056062A1 (en) * | 2017-09-20 | 2019-03-28 | The Bionics Institute Of Australia | SUPERPARTICLES IMPROVED |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4468498A (en) | 1980-06-12 | 1984-08-28 | Rohm And Haas Company | Sequential heteropolymer dispersion and a particulate materal obtainable therefrom, useful in coating compositions as a thickening and/or opacifying agent |
| US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
| US5157084A (en) | 1990-10-12 | 1992-10-20 | The Dow Chemical Company | Process of making hollow polymer latex particles |
| US5521253A (en) | 1990-10-12 | 1996-05-28 | The Dow Chemical Company | Hollow polymer latex particles |
| SE9101853D0 (sv) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | Improved tissue ashesive |
| KR960016882A (ko) * | 1994-11-01 | 1996-06-17 | 강재헌 | 치주염치료를 위한 서방출형 생분해성 제제 |
| JP4116683B2 (ja) * | 1997-02-28 | 2008-07-09 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 徐放性局所送達製剤 |
| WO2003065881A2 (en) * | 2002-02-06 | 2003-08-14 | Orbus Medical Technologies Inc. | Medical device with coating that promotes endothelial cell adherence and differentiation |
| WO2006037160A1 (en) | 2004-10-05 | 2006-04-13 | The University Of Melbourne | Porous polyelectrolyte materials |
| CN100558403C (zh) * | 2006-10-23 | 2009-11-11 | 中国科学院理化技术研究所 | 双壳层药物缓控释载体材料及其制备方法和用途 |
| BRPI0806803A2 (pt) * | 2007-01-19 | 2011-09-13 | Iams Company | composição e método de ingrediente sensìvel estabilizado |
| CN103467755B (zh) * | 2013-09-18 | 2015-06-17 | 薛巍 | 一种药物缓释水凝胶及其制备方法与用途 |
| WO2018013928A1 (en) * | 2016-07-14 | 2018-01-18 | University Hospitals Cleveland Medical Center | Compositions and methods for collagen-based sutures and antibacterial coatings |
| CN108384031B (zh) * | 2017-06-27 | 2020-10-27 | 中南民族大学 | 一种缓释水凝胶载体材料的制备方法和应用 |
| CN107375196B (zh) * | 2017-07-26 | 2020-02-07 | 暨南大学 | 一种含儿茶酚基天然多糖复合水凝胶载体及其制备方法 |
| CN107865822A (zh) * | 2017-08-25 | 2018-04-03 | 中南民族大学 | 一种掺入纳米介孔二氧化硅的水凝胶药物缓释载体材料的制备方法和应用 |
-
2020
- 2020-03-19 EP EP20772821.3A patent/EP3941442A4/en active Pending
- 2020-03-19 AU AU2020242921A patent/AU2020242921B2/en active Active
- 2020-03-19 US US17/437,442 patent/US12551450B2/en active Active
- 2020-03-19 JP JP2021556581A patent/JP2022525945A/ja active Pending
- 2020-03-19 CN CN202080028418.7A patent/CN114040753A/zh active Pending
- 2020-03-19 WO PCT/AU2020/050260 patent/WO2020186304A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019056062A1 (en) * | 2017-09-20 | 2019-03-28 | The Bionics Institute Of Australia | SUPERPARTICLES IMPROVED |
Non-Patent Citations (2)
| Title |
|---|
| MA et al.: "Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery", ACS APPLIED MATERIALS & INTERFACES, 2018, vol. 10, no. 37, pages 31019 - 31031, DOI: 10.1021/acsami.8b10415 * |
| MAINA et al.: "Mold-Templated Inorganic-Organic Hybrid Supraparticles for Codelivery of Drugs", BIOMACROMOLECULES, 2014, vol. 15, no. 11, pages 4146 - 4151, DOI: 10.1021/bm501171j * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3941442A4 (en) | 2022-12-21 |
| US12551450B2 (en) | 2026-02-17 |
| US20220168228A1 (en) | 2022-06-02 |
| CN114040753A (zh) | 2022-02-11 |
| JP2022525945A (ja) | 2022-05-20 |
| WO2020186304A1 (en) | 2020-09-24 |
| EP3941442A1 (en) | 2022-01-26 |
| AU2020242921A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250205308A1 (en) | Supraparticles | |
| Pramanik et al. | Chitosan alchemy: transforming tissue engineering and wound healing | |
| US11213490B2 (en) | Encapsulation-free controlled protein release system | |
| US20130196915A1 (en) | Affinity hydrogels for controlled protein release | |
| Ma et al. | Engineering biocoatings to prolong drug release from supraparticles | |
| CN107660220A (zh) | 超支化聚合物和多聚复合物及包含其的dna或rna递送系统 | |
| Li et al. | An injectable, self-healing and degradable hydrogel scaffold as a functional biocompatible material for tissue engineering applications | |
| CN110124103B (zh) | 一种用于组织修复的活性物质缓释材料体系及其制备方法 | |
| Ning et al. | Recent developments in controlled release of antibiotics | |
| AU2020242921B2 (en) | Supraparticle formulations | |
| Lu | Polymer-Ceramic Hybrid Nanoparticles: Promising Strategies for Controlled Drug Release | |
| KR101629563B1 (ko) | 성장인자를 함유한 생분해용 폴리머-쉘화된 메소포러스 나노구가 삽입된 치료용 폼 스캐폴드 | |
| US20240423903A1 (en) | Biodegradable Implant for Sustained Trans-Nasal Delivery of Therapeutic Agents to the Brain | |
| Grigoras | Pullulan-based hydrogels | |
| Martins et al. | Delivery Systems Made of Natural‐Origin Polymers for Tissue Engineering and Regenerative Medicine Applications | |
| Razavi et al. | Naturally based and biologically derived nanobiomaterials | |
| Popa et al. | Chitosan-Pectin Composite Biomaterials: Types, Interactions, Formulations, and Biomedical Applications | |
| Jose et al. | Alginate Hydrogel and Aerogel | |
| Hosseinpour et al. | Nanobiomaterials in Craniofacial Bone Regeneration | |
| Kumar et al. | Polymer implants for gene and drug delivery | |
| Popa et al. | Chitosan-Pectin Composite Biomaterials: Types, Interactions, Formulations, and Biomedical | |
| Nascimento et al. | Hybrid Smart Materials for Topical Drug Delivery: Application of Scaffolds | |
| Hudson | MNV Ravi Kumar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |